The fifth WHO proposed the following classification of MDS: MDS with defining genetic abnormalities (MDS with isolated 5q deletion, with SF3B1 mutation, and TP53 biallelic mutation) and MDS, morphologically defined (include a distinct MDS type, namely hypoplastic MDS (cellularity < 20% in bone marrow) that responds to drugs used for the treatment of those patients (for example hypomethylating agents or possibly lenalidomide, etc.)[1,13]. Here, SF3B1 is linked to myelodysplastic syndrome.